Biomarkers /
EGFR Codon 719 Missense
Overview
EGFR Codon 719 Missense is present in 0.26% of AACR GENIE cases, with lung adenocarcinoma, conventional glioblastoma multiforme, glioblastoma, non-small cell lung carcinoma, and poorly differentiated non-small cell lung cancer having the greatest prevalence [4].
Biomarker-Directed Therapies
EGFR Codon 719 Missense is a predictive biomarker for use of afatinib, capmatinib, crizotinib, dacomitinib, erlotinib, gefitinib, and cetuximab in patients.
Of the therapies with EGFR Codon 719 Missense as a predictive biomarker, 7 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against EGFR Codon 719 Missense or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR Codon 719 Missense serves as an inclusion eligibility criterion in 52 clinical trials, of which 44 are open and 8 are closed. Of the trials that contain EGFR Codon 719 Missense as an inclusion criterion, 12 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 27 are phase 2 (25 open), and 6 are phase 3 (4 open).
Trials with EGFR Codon 719 Missense in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, lung adenocarcinoma, malignant solid tumor, and squamous cell lung carcinoma [5].
Pembrolizumab, pemetrexed, carboplatin, durvalumab, and nivolumab are the most frequent therapies in trials with EGFR Codon 719 Missense as an inclusion criteria [5].
Significance of EGFR Codon 719 Missense in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR Codon 719 Missense present in 1.26% of all non-small cell lung carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 40 clinical trials for non-small cell lung carcinoma, of which 34 are open and 6 are closed. Of the trials that contain EGFR Codon 719 Missense and non-small cell lung carcinoma as inclusion criteria, 10 are phase 1 (8 open), 7 are phase 1/phase 2 (6 open), 19 are phase 2 (17 open), and 4 are phase 3 (3 open) [5].
Afatinib, capmatinib, cetuximab, crizotinib, dacomitinib, erlotinib, and gefitinib have evidence of efficacy in patients with EGFR Codon 719 Missense in non-small cell lung carcinoma [5].
Lung Adenocarcinoma +
EGFR is altered in 26.09% of lung adenocarcinoma patients with EGFR Codon 719 Missense present in 1.46% of all lung adenocarcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 7 clinical trials for lung adenocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain EGFR Codon 719 Missense and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 2 (4 open), and 2 are phase 3 (1 open) [5].
Malignant Solid Tumor +
EGFR is altered in 7.61% of malignant solid tumor patients with EGFR Codon 719 Missense present in 0.25% of all malignant solid tumor patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 6 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].
Breast Carcinoma +
EGFR is altered in 2.76% of breast carcinoma patients with EGFR Codon 719 Missense present in 0.01% of all breast carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].
Melanoma +
EGFR is altered in 6.07% of melanoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR is altered in 25.27% of non-squamous non-small cell lung carcinoma patients with EGFR Codon 719 Missense present in 1.42% of all non-squamous non-small cell lung carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Urothelial Carcinoma +
EGFR is altered in 4.38% of urothelial carcinoma patients with EGFR Codon 719 Missense present in 0.1% of all urothelial carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Bladder Carcinoma +
EGFR is altered in 3.84% of bladder carcinoma patients with EGFR Codon 719 Missense present in 0.06% of all bladder carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Colorectal Carcinoma +
EGFR is altered in 3.22% of colorectal carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Head And Neck Carcinoma +
EGFR is altered in 4.29% of head and neck carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
EGFR is altered in 6.43% of head and neck squamous cell carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Lung Carcinoma +
EGFR is altered in 22.35% of lung carcinoma patients with EGFR Codon 719 Missense present in 1.22% of all lung carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Glioblastoma +
EGFR is altered in 31.54% of glioblastoma patients with EGFR Codon 719 Missense present in 0.49% of all glioblastoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
EGFR is altered in 3.19% of gallbladder carcinoma patients with EGFR Codon 719 Missense present in 0.35% of all gallbladder carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
EGFR is altered in 6.88% of squamous cell lung carcinoma patients with EGFR Codon 719 Missense present in 0.23% of all squamous cell lung carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Small Cell Lung Carcinoma +
EGFR is altered in 9.38% of small cell lung carcinoma patients with EGFR Codon 719 Missense present in 0.18% of all small cell lung carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
WHO Grade III Glioma +
EGFR is altered in 11.3% of WHO grade III glioma patients with EGFR Codon 719 Missense present in 0.13% of all WHO grade III glioma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Adenocarcinoma +
EGFR is altered in 5.93% of gastric adenocarcinoma patients with EGFR Codon 719 Missense present in 0.11% of all gastric adenocarcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Carcinoma +
EGFR is altered in 5.88% of gastric carcinoma patients with EGFR Codon 719 Missense present in 0.11% of all gastric carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Soft Tissue Sarcoma +
EGFR is altered in 1.3% of soft tissue sarcoma patients with EGFR Codon 719 Missense present in 0.04% of all soft tissue sarcoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR is altered in 5.0% of adenocarcinoma of the gastroesophageal junction patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
EGFR is altered in 1.63% of B-cell non-hodgkin lymphoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Carcinoma +
EGFR is altered in 2.41% of bile duct carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Carcinoma +
EGFR is altered in 1.28% of cervical carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
EGFR is altered in 2.2% of cervical squamous cell carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Diffuse Midline Glioma, H3 K27M-Mutant +
EGFR is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Carcinoma +
EGFR is altered in 4.71% of endometrial carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
EGFR is altered in 8.16% of esophageal squamous cell carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hepatocellular Carcinoma +
EGFR is altered in 1.84% of hepatocellular carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
EGFR is altered in 1.36% of high grade ovarian serous adenocarcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Uterine Neoplasm +
EGFR is altered in 3.53% of malignant uterine neoplasm patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Multiple Myeloma +
EGFR is altered in 1.65% of multiple myeloma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Carcinoma +
EGFR is altered in 1.36% of ovarian carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
EGFR is altered in 1.02% of pancreatic adenocarcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Carcinoma +
EGFR is altered in 1.0% of pancreatic carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
EGFR is altered in 1.22% of prostate carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Renal Cell Carcinoma +
EGFR is altered in 1.23% of renal cell carcinoma patients [4].
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.